Redcliffe Lifetech raises Rs 466 crore to expand access to diagnostic tests across India

"Redcliffe's vision of shifting healthcare from treating the sick to enabling wellness will have profound implications for millions," LeapFrog Investments Partner and Global Co-Leader for Health Investments Biju Mohandas said.

Published On 2022-05-07 04:00 GMT | Update On 2022-05-07 04:00 GMT

New Delhi: Leading diagnostics platform Redcliffe Lifetech on Friday said it has raised USD 61 million (around Rs 466 crore) in a funding round led by LeapFrog Investments. Healthquad, Schroders, LC Nueva, Growth Spark Ventures and existing investors Chiratae Ventures and Alkemi Venture Partners also participated in the funding round.The investment will be used to expand its geographic...

New Delhi: Leading diagnostics platform Redcliffe Lifetech on Friday said it has raised USD 61 million (around Rs 466 crore) in a funding round led by LeapFrog Investments. Healthquad, Schroders, LC Nueva, Growth Spark Ventures and existing investors Chiratae Ventures and Alkemi Venture Partners also participated in the funding round.

The investment will be used to expand its geographic reach across the country, with a focus on expanding its low-cost high quality direct-to-consumer diagnostics, into tier 2, 3 and 4 cities, the company said in a statement.

The latest funding will also be used to scale its platform and increase its product offerings to radiology, disease data profiling and lifestyle management, furthering its mission to shift India's healthcare focus from treatment to early diagnosis and prevention, it added.

Read also: Chronic disease management startup Phablecare raises Rs 187 crore in funding round led by Kalaari Capital

"Preventative medicine is the future of health in India, helping to empower the average Indian with the information they need to take charge of their health and wellbeing," Redcliffe Founder Dheeraj Jain noted.

The company has built a one-stop diagnostic shop offering a very wide selection of tests to choose from and delivering care closer to the customer and the fresh investment will help to scale up rapidly to achieve the goal to reach over 50 crore Indians within the next five years, he added.

Read also: Govt grants Rs 24 crore to Epygen Biotech to begin cost-effective COVID vaccine trials

"Redcliffe's vision of shifting healthcare from treating the sick to enabling wellness will have profound implications for millions. We're thrilled to be partnering with Dheeraj and his management team to further scale their reach across India," LeapFrog Investments Partner and Global Co-Leader for Health Investments Biju Mohandas said.

Redcliffe currently has a network of 22 laboratories across 14 cities in the country.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Redcliffe Lifetech raises Rs 466 crore to expand access to diagnostic tests across India

"Redcliffe's vision of shifting healthcare from treating the sick to enabling wellness will have profound implications for millions," LeapFrog Investments Partner and Global Co-Leader for Health Investments Biju Mohandas said.

Similar News